GSK's single-tablet, dual-drug HIV drug Dovito® approved for expanded indications
Time of Update: 2022-08-15
Agency approval as a complete regimen for the treatment of HIV-1-infected adults and adolescents over 12 years of age who have achieved virological suppression On May 11, GlaxoSmithKline (GSK) announced that its innovative single-tablet dual-drug HIV treatment program, Dovito (generic name: lamivudine and dolutegravir), has been officially approved by the National Medical Products Administration of China for its expanded indications.
New drug application for RTK inhibitor for the treatment of renal cell carcinoma
Time of Update: 2022-01-10
Recently, Allarity Therapeutics announced that it has submitted a New Drug Application (NDA) to the US FDA to seek approval of the receptor tyrosine kinase (RTK) inhibitor dovitinib for the third-line treatment of renal cell carcinoma (RCC) .
Significant progress in Hepatology
Time of Update: 2021-11-15
On October 14, 2021, the Guo Jiao team of Guangdong Pharmaceutical University published an online research paper entitled "Hepatocyte glutathione S-transferase mu 2 prevents non-alcoholic steatohepatitis by suppressing ASK1 signaling" in the Journal of Hepatology (IF=25.
Baishi Meishi Guibao oral S1P subject regulator Zeposia EU application for new
Time of Update: 2021-01-04
"TRUE NORTH is a multi-center, randomized, double-blind, placebo-controlled Phase III trial that investigates the efficacy and safety of Zeposia 1mg in moderate to severe UC patients who did not respond well to previous treatments.